Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
June 16, 2016 17:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2...
Kura Oncology to Participate in the 2016 JMP Life Sciences Conference
June 14, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences...
Kura Oncology Reports First Quarter 2016 Financial Results
May 11, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Kura Oncology Cleared for Quotation on the OTCQB
September 16, 2015 07:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid...
Kura Oncology to Present at the 2015 Wedbush PacGrow Healthcare Conference
August 05, 2015 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and...